CAMBRIDGE, Mass.--(BUSINESS WIRE)--Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that as part of its commitment to sustainability, the Company will work to achieve net-zero carbon emissions globally by 2030.
“We believe that each corporation around the world needs to be part of the solution in addressing climate change and our first step is to commit to net-zero carbon emissions. We are proud of this ambitious goal that we have set for ourselves, as we aim to put Moderna among the global leaders in managing the impact of waste from our business and decreasing the natural resources we use, to promote long-term, sustainable growth for the planet and our organization. We look forward to working to achieve this goal with all of our partners,” said Stéphane Bancel, Chief Executive Officer of Moderna. “As we continue through this period of accelerated growth, we will continue to make corporate responsibility a critical part of who we are and what we do with a sense of purpose. From the delivery of our COVID-19 vaccine to our investment in renewable energy, we always seek to do the right thing, the right way. It is critical for a high-growth company like Moderna to set such a goal. We will build Moderna in a way that minimizes our impact on the planet while delivering innovative vaccines to prevent people from getting sick and medicines to help those who have diseases.”
As part of Moderna’s ongoing Corporate Social Responsibility efforts to reduce its environmental impact, the Company is implementing key initiatives that include:
- Establishing baseline metrics including Energy, Waste and Water to inform the creation and implementation of a comprehensive ESG program.
- Assessing the overall utilities infrastructure of the Moderna Technology Center manufacturing site in Norwood, Massachusetts to formulate a scope and timeline to reduce its carbon footprint
- Committing to the direct use of renewable energy in U.S. facilities beginning in 2021, and to the extent renewable energy is not used, the Company will offset non-renewable electricity consumption through renewable energy credits (RECs).
- Investing in the new Moderna Science Center at 325 Binney Street in Cambridge, Massachusetts. The high-performance building is targeting LEED Platinum Core & Shell and LEED Zero Energy certifications and is designed to be the most sustainable commercial lab building in Cambridge. To achieve this, the building will include ultra-efficient building systems with acoustical and light pollution mitigation measures.
- Incorporating sustainable design and construction elements into all new projects, starting with our new manufacturing plants in Canada and in Africa, including access to renewable energy sources and LEED Certifications as part of site selection criteria.
- Encouraging green transportation to our employees by offering fully subsidized public transport, bike sharing and free electric vehicle charging stations across all campuses.
- We will work with each of our suppliers to ensure that they also move to net-zero carbon.
- Partner across industries to seek innovative solutions and achieve net-zero targets.
The Company is making this announcement as the 2021 United Nations Climate Change Conference (COP26) is ongoing in Glasgow, Scotland. To learn more about Moderna’s Corporate Social Responsibility, please visit the Responsibility section of Moderna’s website.
In 10 years since its inception, Moderna has transformed from a science research-stage company advancing programs in the field of messenger RNA (mRNA), to an enterprise with a diverse clinical portfolio of vaccines and therapeutics across six modalities, a broad intellectual property portfolio in areas including mRNA and lipid nanoparticle formulation, and an integrated manufacturing plant that allows for both clinical and commercial production at scale and at unprecedented speed. Moderna maintains alliances with a broad range of domestic and overseas government and commercial collaborators, which has allowed for the pursuit of both groundbreaking science and rapid scaling of manufacturing. Most recently, Moderna’s capabilities have come together to allow the authorized use of one of the earliest and most-effective vaccines against the COVID-19 pandemic.
Moderna’s mRNA platform builds on continuous advances in basic and applied mRNA science, delivery technology and manufacturing, and has allowed the development of therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases and autoimmune diseases. Moderna has been named a top biopharmaceutical employer by Science for the past seven years. To learn more, visit www.modernatx.com.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including regarding: the Company’s goal of achieving net-zero carbon emissions globally by 2030; the Company’s plans for achieving sustainable growth; and the execution on those objectives, including initiatives to implement sustainability practices into the Company’s facilities. The forward-looking statements in this press release are neither promises nor guarantees, and you should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, many of which are beyond Moderna’s control and which could cause actual results to differ materially from those expressed or implied by these forward-looking statements. These risks, uncertainties, and other factors include those other risks and uncertainties described under the heading “Risk Factors” in Moderna’s most recent Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission (SEC) and in subsequent filings made by Moderna with the SEC, which are available on the SEC’s website at www.sec.gov. Except as required by law, Moderna disclaims any intention or responsibility for updating or revising any forward-looking statements contained in this press release in the event of new information, future developments or otherwise. These forward-looking statements are based on Moderna’s current expectations and speak only as of the date hereof.